These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7679737)

  • 1. Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers.
    Preston KL; Bigelow GE
    J Pharmacol Exp Ther; 1993 Feb; 264(2):813-23. PubMed ID: 7679737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
    Jones HE; Bigelow GE; Preston KL
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment with hydromorphone, a mu-opioid agonist, does not alter the acute behavioral and physiological effects of ethanol in humans.
    Rush CR
    Alcohol Clin Exp Res; 2001 Jan; 25(1):9-17. PubMed ID: 11198720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug discrimination in human postaddicts: agonist-antagonist opioids.
    Preston KL; Bigelow GE; Bickel WK; Liebson IA
    J Pharmacol Exp Ther; 1989 Jul; 250(1):184-96. PubMed ID: 2473187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure.
    Preston KL; Bigelow GE
    J Pharmacol Exp Ther; 1994 Oct; 271(1):48-60. PubMed ID: 7525929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1987 Mar; 240(3):900-10. PubMed ID: 3559982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
    Lamas X; Farre M; Cami J
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination.
    Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1992 Apr; 261(1):62-71. PubMed ID: 1373189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment.
    Stoops WW; Lofwall MR; Nuzzo PA; Craig LB; Siegel AJ; Walsh SL
    Psychopharmacology (Berl); 2012 Oct; 223(4):427-38. PubMed ID: 22623016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.
    Walsh SL; Chausmer AE; Strain EC; Bigelow GE
    Psychopharmacology (Berl); 2008 Jan; 196(1):143-55. PubMed ID: 17909753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination.
    Preston KL; Bigelow GE
    J Pharmacol Exp Ther; 2000 Oct; 295(1):114-24. PubMed ID: 10991968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans.
    Walsh SL; Sullivan JT; Preston KL; Garner JE; Bigelow GE
    J Pharmacol Exp Ther; 1996 Nov; 279(2):524-38. PubMed ID: 8930154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
    Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
    Carroll CP; Walsh SL; Bigelow GE; Strain EC; Preston KL
    Exp Clin Psychopharmacol; 2006 May; 14(2):109-20. PubMed ID: 16756415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
    Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
    J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the subjective, psychomotor and physiological effects of intravenous pentazocine and morphine in normal volunteers.
    Zacny JP; Hill JL; Black ML; Sadeghi P
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1197-207. PubMed ID: 9732379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers.
    Walker DJ; Zacny JP
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1454-64. PubMed ID: 10336539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminative-stimulus effects of the low efficacy mu agonist nalbuphine.
    Walker EA; Young AM
    J Pharmacol Exp Ther; 1993 Oct; 267(1):322-30. PubMed ID: 8229759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.